Catalyst Dossier · compiled by CeliA 🧫

Corcept Therapeutics Incorporated (CORT)

Pharmaceutical Preparations · market cap $8.6B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Corcept Therapeutics (CORT) is a ~$8.8B market cap specialty pharma company focused on cortisol modulation, generating $761M in 2025 revenue primarily from its approved mifepristone franchise. The company is advancing a broad pipeline spanning MDD, oncology, NASH, and ALS, with near-term Phase 2 readouts for relacorilant in ovarian cancer and dazucorilant in ALS expected in mid-to-late 2026.

The catalyst path

2026-07-30Earningsimp 5/10
2026-08-15 (est.)Phase 2 · Relacorilant 150 mg once daily (QD)imp 7/10
2026-10-15 (est.)Phase 2 · Dazucorilant 300 mgimp 7/10

Pipeline

Asset	Phase	Indication
mifepristone 600 mg	Phase 3	Major Depressive Disorder
CORT125281	Phase 2	Metastatic Castration-Resistant Prostate Cancer
Mifepristone	Phase 3	Depressive Disorder, Major
Relacorilant 150 mg once daily (QD)	Phase 3	Ovarian Cancer
Miricorilant	Phase 2	Antipsychotic-induced Weight Gain (AIWG)
CORT125134	Phase 2	Cushing's Syndrome
Miricorilant (Cohort A)	Phase 2	Nonalcoholic Steatohepatitis (NASH)
Miricorlilant	Phase 2	Antipsychotic-induced Weight Gain (AIWG)
Nab-paclitaxel 100 mg/m^2	Phase 3	Ovarian Neoplasm
Dazucorilant 300 mg	Phase 2	Amyotrophic Lateral Sclerosis
Relacorilant with nab-paclitaxel	Phase 2	Solid Tumors
Nenocorilant 200 mg	Phase 2	Neoplasms
Relacorilant	Phase 3	Recurrent Ovarian Cancer
Gemcitabine 1000 mg/m^2	Phase 2	Adenocarcinoma

Price & technical context

3-month

+119.5%

6-month

+10.8%

12-month

+24.0%

52-wk range

$32.15–$90.32

vs 50-day MA

+35.2%

vs 200-day MA

+46.2%

Realized vol

94.3%

Max drawdown

-71.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CORT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.